Neoadjuvant (presurgical) therapy for renal cell carcinoma: A new treatment paradigm for locally advanced and metastatic disease

Cancer

Volumn 115, Issue SUPPL. 10, 2009, Pages 2355-2360

  Wood, Christopher G ^a   Margulis, Vitaly ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Neoadjuvant therapy; Nephrectomy; Renal cell carcinoma; Targeted therapy; Transduction pathways

Indexed keywords

BEVACIZUMAB; SORAFENIB; SUNITINIB;

ADJUVANT THERAPY; ADVANCED CANCER; CANCER PATIENT; CANCER THERAPY; CLINICAL PROTOCOL; CONFERENCE PAPER; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; DISEASE MODEL; HUMAN; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; METASTASIS; MORBIDITY; MORTALITY; NEPHRECTOMY; OUTCOME ASSESSMENT; PARAMETER; PERIOPERATIVE PERIOD; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SAFETY; TREATMENT RESPONSE;

CARCINOMA, RENAL CELL; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; DRUG DELIVERY SYSTEMS; HUMANS; KIDNEY NEOPLASMS; NEOADJUVANT THERAPY; NEOPLASM METASTASIS; NEPHRECTOMY;

EID: 65949111709     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.24240     Document Type: Conference Paper

References (15)

1. Leibovich BC, Blute ML. Surgical management of renal cell carcinoma. Semin Oncol. 2006;33:552-562.
2. Wood CG. The role of cytoreductive nephrectomy in the management of metastatic renal cell carcinoma. Urol Clin North Am. 2003;30:581-588.
3. Mickisch GH, Garin A, van Poppel H, et al. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renalcell carcinoma: a randomised trial. Lancet. 2001;358:966-970.
4. Flanigan RC, Salmon SE, Blumenstein BA, et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med. 2001;345:1655-1659. (Pubitemid 33126820)
5. Vogl UM, Zehetgruber H, Dominkus M, et al. Prognostic factors in metastatic renal cell carcinoma: metastasectomy as independent prognostic variable. Br J Cancer. 2006;95:691-698.
6. Wood CG. Adjuvant approaches to renal cell carcinoma. Clin Adv Hematol Oncol. 2008;6:19-21.
7. Kunkle DA, Haas NB, Uzzo RG. Adjuvant therapy for high-risk renal cell carcinoma patients. Curr Urol Rep. 2007;8:19-30.
8. Walther MM, Yang JC, Pass HI, et al. Cytoreductive surgery before high dose interleukin-2 based therapy in patients with metastatic renal cell carcinoma. J Urol. 1997;158:1675-1678. (Pubitemid 27433129)
9. Jonasch E. Presurgical therapy in metastatic renal cell carcinoma. Expert Rev Anticancer Ther. 2007;7:73-78.
10. Wood CG. Multimodal approaches in the management of locally advanced and metastatic renal cell carcinoma: combining surgery and systemic therapies to improve patient outcome. Clin Cancer Res. 2007;13:697s-702s.
11. Margulis V, Matin SF, Tannir N, et al. Surgical morbidity associated with administration of targeted molecular therapies before cytoreductive nephrectomy or resection of locally recurrent renal cell carcinoma. J Urol. 2008;180:94-98.
12. Karakiewicz PI, Suardi N, Jeldres C, et al. Neoadjuvant Sutent induction therapy may effectively down-stage renal cell carcinoma atrial thrombi. Eur Urol. 2008;53:845-848.
13. Shuch B, Riggs SB, Larochelle JC, et al. Neoadjuvant targeted therapy and advanced kidney cancer: observations and implications for a new treatment paradigm. BJU Int. 2008;102:692-696.
14. van der Veldt AA, Meijerink MR, van den Eertwegh AJ, et al. Sunitinib for treatment of advanced renal cell cancer: primary tumor response. Clin Cancer Res. 2008;14:2431-2436.
15. Wagner JR, Walther MM, Linehan WM, et al. Interleukin-2 based immunotherapy for metastatic renal cell carcinoma with the kidney in place. J Urol. 1999;162:43-45. (Pubitemid 29420876)